Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001206949 | SCV001378283 | pathogenic | Ornithine carbamoyltransferase deficiency | 2019-08-02 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 1 of the OTC gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in OTC are known to be pathogenic (PMID: 10946359, 16786505). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individuals affected with OTC deficiency (PMID: 16786505, 9143919). ClinVar contains an entry for this variant (Variation ID: 97313). This variant is not present in population databases (ExAC no frequency). |
Gen |
RCV000083559 | SCV000115645 | pathogenic | not provided | no assertion criteria provided | not provided | Converted during submission to Pathogenic. |